Business
IGC Pharma Adds Ichor Research as New Site for CALMA Phase 2 Alzheimer's Trial
POTOMAC, MD / ACCESS Newswire / September 29, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced the addition of a new clinical trial site to its ongoing Phase 2 study evaluating IGC-AD1, an investigational drug candidate for treating agitation ...
About this update from Igc Pharma, Inc.
[{"type":"text","content":"POTOMAC, MD / ACCESS Newswire / September 29, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced the addition of a new clinical trial site to its ongoing Phase 2 study evaluating IGC-AD1, an investigational drug candidate for treating agitation in Alzheimer's disease. The new site, Ichor Research, located in Syracuse, New York, is led by Principal Investigator Dr. Karl F. Hafner, M.D.","length":400,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":"IGC Pharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":1504,"height":890,"url":"https://media.zenfs.com/en/accesswire.ca/ba10e947333607fca79e5d128798f6f2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Z1mTrgBbNv0Fe3Ozt5pnWA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU2ODtjZj13ZWJw/https://media.zenfs.com/en/accesswire.ca/ba10e947333607fca79e5d128798f6f2","width":960,"height":568},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/kaHNkUzn_Dw0tbOhGvQb3Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xNDIwO2NmPXdlYnA-/https://media.zenfs.com/en/accesswire.ca/ba10e947333607fca79e5d128798f6f2","width":1200,"height":710}}},{"type":"text","content":"Dr. Hafner brings years of experience in clinical research and patient care, particularly in the field of neurodegenerative conditions. Ichor Research began enrolling eligible participants for the CALMA trial immediately.","length":221,"tagName":"p"},{"type":"text","content":"The CALMA Phase 2 trial is a randomized, double-blind, placebo-controlled study designed to evaluate the safety and efficacy of IGC-AD1 in reducing agitation symptoms in individuals living with Alzheimer's disease. Agitation is one of the most prevalent and distressing behavioral symptoms in Alzheimer's patients, often accelerating disease progression and increasing caregiver burden.","length":394,"tagName":"p"},{"type":"text","content":""We are proud to partner with Ichor Research as part of our commitment to expand access to innovative treatment options for patients and caregivers," said Ram Mukunda, CEO of IGC Pharma. "Dr. Hafner, and the team at Ichor bring valuable expertise that will help advance the CALMA trial."","length":307,"tagName":"p"},{"type":"text","content":"Contact Information:","length":20,"tagName":"p"},{"type":"text","content":"Kristen Stebbins...